IP Verse

Neurodevelopmental Disorder Therapy - EP3407880

The patent EP3407880 was granted to Anavex Life Sciences on Aug 17, 2022. The application was originally filed on Jan 24, 2017 under application number EP17703579A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3407880

ANAVEX LIFE SCIENCES
Application Number
EP17703579A
Filing Date
Jan 24, 2017
Status
Opposition Rejected
Sep 6, 2024
Grant Date
Aug 17, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZMay 17, 2023TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2015152410
DESCRIPTIONUS2015265554
DESCRIPTIONUS7994127
DESCRIPTIONUS9180106
INTERNATIONAL-SEARCH-REPORTGR1004208
INTERNATIONAL-SEARCH-REPORTWO9730983
OPPOSITIONFR2897535

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- FITZGERALD ET AL., "Rett syndrome and associated movement disorders", MOVEMENT DISORDERS, (1990), vol. 5, no. 3, pages 195 - 202-
DESCRIPTION- GUY ET AL., "Reversal of Neurological Defects in a Mouse Model of Rett Syndrome", SCIENCE, (2007), vol. 315, no. 5815, pages 1143 - 7-
DESCRIPTION- LOMBARDI ET AL., "MECP2 disorders: from the clinic to mice and back", J CLIN INVEST., (20150803), vol. 125, no. 8, pages 2914 - 23-
DESCRIPTION- MALLON ET AL., "EuroPhenome and EMPReSS: online mouse phenotyping resource", NUCLEIC ACIDS RES., (20070928), vol. 36, pages D715 - 8-
DESCRIPTION- MORGAN ET AL., "EuroPhenome: a repository for high-throughput mouse phenotyping data", NUCLEIC ACIDS RES., (20091123), vol. 38, pages D577 - 85-
DESCRIPTION- POHODICH ET AL., "Rett syndrome: disruption of epigenetic control of postnatal neurological functions", HUM MOL GENET., (20150609), vol. 24, no. R1-
DESCRIPTION- RICCERI ET AL., "Mouse models of Rett syndrome: From behavioural phenotyping to preclinical evaluation of new therapeutic approaches", BEHAVIOURAL PHARMACOLOGY, (2008), vol. 19, no. 5-6, pages 501 - 17-
DESCRIPTION- TRAPPE ET AL., "MECP2 Mutations in Sporadic Cases of Rett Syndrome Are Almost Exclusively of Paternal Origin", THE AMERICAN JOURNAL OF HUMAN GENETICS, vol. 68, no. 5, pages 1093 - 101-
DESCRIPTION- TROPEA ET AL., "Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2009), vol. 106, no. 6, doi:doi:10.1073/pnas.0812394106, pages 2029 - 34, XP055122225
INTERNATIONAL-SEARCH-REPORT- Anavex Life Sciences, "Assessment of ANAVEX 2-­-73 in a MECP2 Re5 Syndrome Mouse Model 2016 Epilepsy Pipeline Conference February 26 th 2016", (20160226), URL: http://www.anavex.com/my_uploads/Assessment-of-Anavex-2-73-in-a-MECP2-Rett-Syndrome-Mouse-Model.pdf, (20170324), XP055358593 [XP] 1-7 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- Eveline Hagebeuk, "UvA-DARE (Digital Academic Repository)", Rett Syndrome: Neurologic and metabolic aspects - PhD thesis, (20131107), pages 12 - 33, URL: https://pure.uva.nl/ws/files/2312678/129068_05.pdf, (20170324), XP055358580 [A] 1-6 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- N Rebowe, "ANAVEX 2-73 as a Potential Treatment for Rett Syndrome and Other Pediatric or Infantile Disorders with Seizure Pathology", (20160623), URL: https://s3.amazonaws.com/foxg1-sbfq/Rett%20and%20infantile%20Spasms%20AV2-73%20Presentation.pdf, (20170324), XP055358591 [XP] 1-7 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- MATTHEW J. LYST ET AL, "Rett syndrome: a complex disorder with simple roots", NATURE REVIEWS GENETICS, GB, (20150303), vol. 16, no. 5, doi:10.1038/nrg3897, ISSN 1471-0056, pages 261 - 275, XP055358535 [A] 1-7 * the whole document *
OPPOSITION- Anonymous, "Alzheimer's Disease (AD)", DRUGBANK, (20230101), DRUGBANK, URL: https://go.drugbank.com/indications/DBCOND0049114, (20240226), XP093134678-
OPPOSITION- Anonymous, "ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints", ANAVEX Life Sciences Corp, (20220201), ANAVEX Life Sciences Corp, URL: https://www.anavex.com/post/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints, (20240226), XP093134667-
OPPOSITION- Anonymous, "Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome", Anavex Life Sciences Corps, (20230628), Anavex Life Sciences Corps, (20240226), XP093134673-
OPPOSITION- K. RUSCHER et al., "The involvement of the sigma-1 receptor in neurodegeneration and Neurorestoration", Journal of Pharmacological Sciences, (20150000), vol. 127, pages 30 - 35, XP002801665-
OPPOSITION- Daniela Valenti, Lidia de Bari, Bianca De Filippis, Alexandra Henrion-Caude, Rosa Anna Vacca, "Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: An overview of Down syndrome, autism, Fragile X and Rett syndrome", NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, PERGAMON PRESS LTD., AMSTERDAM, NL, AMSTERDAM, NL , (20141001), vol. 46, doi:10.1016/j.neubiorev.2014.01.012, ISSN 0149-7634, pages 202 - 217, XP093159139
OPPOSITION- Kaufmann Walter E.; Sprouse Jeffrey; Rebowe Nell; Hanania Taleen; Klamer Daniel; Missling Christopher U., "ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR., ELSEVIER., US, US , (20191105), vol. 187, doi:10.1016/j.pbb.2019.172796, ISSN 0091-3057, XP085903567
OPPOSITION- SU TP et al., "The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems", Trends Pharmacol Sci, (20160000), vol. 37, no. 4, doi:10.1016/j.tips.2016.01.003, pages 262 - 78, XP029475504
OPPOSITION- Ette Ene I., Fadiran Emmanuel O., Missling Christopher, Hammond Edward, "The new big is small: Leveraging knowledge from small trials for rare disease drug development: Blarcamesine for Rett syndrome", British journal of clinical pharmacology, BLACKWELL SCIENTIFIC PUBL., GB, GB , (20230803), doi:10.1111/bcp.15843, ISSN 0306-5251, pages 1 - 15, XP093134665
OPPOSITION- VILLARD et al., "Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigmal (sigma1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative", Journal of Psychopharmacology, vol. 25, no. 8, doi:10.1177/0269881110379286, pages 1101 - 1117, XP009169910
OPPOSITION- Teruo Hayashi, Shang-Yi Tsai, Tomohisa Mori, Michiko Fujimoto, Tsung-Ping Su, "Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders", Expert Opinion on Therapeutic Targets, doi:10.1517/14728222.2011.560837, ISSN 14728222, pages 1 - 21, XP055104488
OPPOSITION- LAHMY VALENTINE ET AL, "Mitochondrial protection by the mixed muscarinic/[sigma]1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in A[beta]25-35 peptide-injected mice, a nontransgenic Alzheimer's disease model.", FRONTIERS IN CELLULAR NEUROSCIENCE, Frontiers Research Foundation, CH, CH , (20150120), vol. 8, no. 463, doi:10.3389/fncel.2014.00463, ISSN 1662-5102, pages 1 - 11, XP002761608

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents